Clinical trial
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73…
NCT00483223 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00483223 |
|---|---|
| Title | Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response |
| Official title | A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute North Shore Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin, carboplatin |
| Enrollment | 86 |
| Start date | Jun 1, 2007 |
| Primary completion | Jun 1, 2014 |
| Completion | Jun 1, 2017 |
| First posted | Jun 6, 2007 |
| Last update posted | Aug 25, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: